CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Previfenon®Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2819 favipiravir Wiki 1.00
drug2331 Standard of care therapy Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD Study

The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.

NCT04446065 COVID-19 SARS-CoV2 Drug: Previfenon® Drug: Placebo

Primary Outcomes

Description: A positive case or event of COVID-19 is defined as a patient with acute respiratory illness presenting fever (37.8º C); at least one of the following symptoms: odynophagia, cough, myalgia, or dyspnea; and a specific positive rtPCR test for SARS-CoV-2.

Measure: Event of clinical acute respiratory disease with a diagnosis of COVID-19 confirmed with rtPCR

Time: The date for censoring a case will be defined as that date when the rtPCR test results positive minus 4 days, with the aim to calculate the time free of clinically defined COVID-19 infection over 40 to 70 days of intervention

Secondary Outcomes

Description: Rate of positive cases for IgM and IgG anti-SARS-CoV-2 measured by immunochromatographic test in treatment and placebo group at the end of the study

Measure: Rate of positive cases for IgM and IgG anti-SARS-CoV-2

Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of intervention

Description: Rate of asymptomatic cases defined as a positive rtPCR for SARS-CoV-2 viral RNA but with no symptoms of COVID-19 in treatment and placebo group at the end of the study, and a composite outcome considering symptomatic and asymptomatic cases (i.e. all cases with positive rtPCR test)

Measure: Composite outcome considering symptomatic and asymptomatic cases with positive rtPCR test

Time: Positive cases in each two-weeks examination and to the end of the study over 40 to 70 days of intervention

Description: Rate of hospitalizations due to any acute respiratory infection at the end of the study

Measure: Hospitalization due to any acute respiratory infection

Time: Positive cases in each two-week examination visit and to the end of the study over 40 to 70 days of intervention

Description: Global frequency of events of upper and lower airway respiratory infections

Measure: Event of upper and lower airway respiratory infection

Time: Positive cases in each two-week examination and to the end of the study over 40 to 70 days of intervention

Other Outcomes

Description: Registry of Visual Analogue Scale (VAS) in the log diary of every healthcare worker for the following selected symptoms: cough, muscle pain (myalgia); difficulty breathing (dyspnea); loss of smell (anosmia); loss of taste (ageusia); pain when swallowing (odynophagia, sore throat); and finally headache

Measure: Exploratory outcome: Frequency and intensity of selected symptoms for COVID-19

Time: Different VAS scores calculated each two-week examination visit over 40 to 70 days of intervention

Description: Elevation of liver enzymes over 5 times the normal value

Measure: Primary safety outcome: event of major hepatic harm

Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of intervention.

Description: Elevation of liver enzymes over 5 times the normal value

Measure: Event of liver enzymes over 3 times the normal value

Time: Cases accounted by liver profile lab test in each two-week examination visit over 40 to 70 days of intervention

Description: Any adverse event reported over the intervention period

Measure: Frequency of adverse events

Time: Records of self-reported adverse effects on log dairy accounted in each examination visit over 40 to 70 days of intervention


No related HPO nodes (Using clinical trials)